Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ENTO logo ENTO
Upturn stock ratingUpturn stock rating
ENTO logo

Entero Therapeutics, Inc. (ENTO)

Upturn stock ratingUpturn stock rating
$2.15
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: ENTO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $36

1 Year Target Price $36

Analysts Price Target For last 52 week
$36 Target price
52w Low $0.84
Current$2.15
52w High $2.78

Analysis of Past Performance

Type Stock
Historic Profit -66.01%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.42M USD
Price to earnings Ratio -
1Y Target Price 36
Price to earnings Ratio -
1Y Target Price 36
Volume (30-day avg) 1
Beta 0.81
52 Weeks Range 0.84 - 2.78
Updated Date 08/29/2025
52 Weeks Range 0.84 - 2.78
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -11.97

Earnings Date

Report Date 2025-08-20
When -
Estimate -
Actual -0.6802

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -3.32%
Return on Equity (TTM) -24.28%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 65927673
Price to Sales(TTM) -
Enterprise Value 65927673
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.1
Shares Outstanding 1588580
Shares Floating 1482030
Shares Outstanding 1588580
Shares Floating 1482030
Percent Insiders 7.3
Percent Institutions 2.56

ai summary icon Upturn AI SWOT

Entero Therapeutics, Inc.

stock logo

Company Overview

overview logo History and Background

As of my knowledge cut-off date, Entero Therapeutics, Inc. is not a publicly traded company in the US. There is no available information on its founding year, milestones, and evolution as a public entity.

business area logo Core Business Areas

leadership logo Leadership and Structure

Since Entero Therapeutics, Inc. is not a public company with available information on their core businesses, the following is not applicable.

Top Products and Market Share

overview logo Key Offerings

Market Dynamics

industry overview logo Industry Overview

Without knowing Entero Therapeutics' business area, an industry overview cannot be provided.

Positioning

Without knowing Entero Therapeutics' business area, their market positioning cannot be determined.

Total Addressable Market (TAM)

Without knowing Entero Therapeutics' business area, an estimate of the TAM is unavailable.

Upturn SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

A competitive landscape analysis cannot be performed without knowing Entero Therapeutics' business and key competitors.

Growth Trajectory and Initiatives

Historical Growth: Growth trends are unavailable for a private company.

Future Projections: Future projections are unavailable for a private company.

Recent Initiatives: Recent initiatives are unavailable for a private company.

Summary

Because Entero Therapeutics, Inc. appears to be a private company, limited information is available to assess its current state. Therefore, judging its strengths, weaknesses, opportunities, and threats is not possible without further financial and operational data. A more detailed analysis would require access to the company's internal records.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Publicly available databases and search engines.

Disclaimers:

The analysis is based on limited publicly available information. The absence of data may not accurately reflect the company's true status. This is not financial advice. Please consult a professional.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Entero Therapeutics, Inc.

Exchange NASDAQ
Headquaters Boca Raton, FL, United States
IPO Launch date 2016-10-11
CEO & Director Mr. Richard Joel Paolone
Sector Healthcare
Industry Biotechnology
Full time employees 2
Full time employees 2

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. It develops Adrulipase, an oral, non-systemic, and biologic capsule that is in Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP), as well as a recombinant lipase enzyme that enables the digestion of fats and other nutrients in CF and CP patients with EPI. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.